Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

[1]  J. Drewe,et al.  A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients , 2015, SpringerPlus.

[2]  A. Giobbie-Hurder,et al.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.

[3]  K. Gelmon,et al.  Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Gelber,et al.  Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. , 2013, Breast.

[5]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[6]  J. Forbes,et al.  Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Bowen,et al.  Psychometric properties of a tool for measuring hormone‐related symptoms in breast cancer survivors , 2006, Psycho-oncology.

[8]  J. Cuzick,et al.  Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer , 2006, Breast Cancer Research and Treatment.

[9]  D. Rousseau,et al.  On the Receiving End , 2006 .

[10]  R. Coombes,et al.  Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Stockler,et al.  Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? , 2005, British Journal of Cancer.

[12]  M. Hickey,et al.  Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. , 2005, The Lancet. Oncology.

[13]  M. Stockler,et al.  What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? , 2005, The Lancet. Oncology.

[14]  J. Sloan,et al.  Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical Trials , 2004, Journal of biopharmaceutical statistics.

[15]  J. Cuzick,et al.  Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Sauerbrei,et al.  Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Rutqvist,et al.  Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M Sullivan,et al.  Clinical relevance of single item quality of life indicators in cancer clinical trials , 2001, British Journal of Cancer.

[19]  J. Cuzick,et al.  Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Costantino,et al.  Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Susan R. Johnson,et al.  Symptom Relief and Side Effects of Postmenopausal Hormones: Results From the Postmenopausal Estrogen/Progestin Interventions Trial , 1998, Obstetrics and gynecology.

[22]  C. Hürny,et al.  Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. , 1998, British Journal of Cancer.

[23]  R. Gelber,et al.  Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach , 1998 .

[24]  R. Gelber,et al.  Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. , 1996, Medical care.

[25]  C. Redmond,et al.  Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. , 1995, Journal of the National Cancer Institute.

[26]  A. Goldhirsch,et al.  The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials , 1993, Supportive Care in Cancer.

[27]  P. Butow,et al.  On the receiving end. IV: Validation of quality of life indicators. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  L. Radloff.  The CES-D Scale , 1977 .

[29]  J. Bernhard,et al.  Patients' estimation of overall treatment burden: why not ask the obvious? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Stewart,et al.  Measuring Functioning and Well-Being: The Medical Outcomes Study Approach , 1992 .